AXSM Valuation

Axsome Therapeutics Inc

Add to Watchlist

Advanced Chart

101.480

-3.49(-3.325%)1D

Overview
Forecast
Valuation
Earnings

AXSM Relative Valuation

AXSM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AXSM is overvalued; if below, it's undervalued.

Historical Valuation

Axsome Therapeutics Inc (AXSM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.64 is considered Undervalued compared with the five-year average of -18.11. The fair price of Axsome Therapeutics Inc (AXSM) is between 636.20 to 654.17 according to relative valuation methord. Compared to the current price of 104.62 USD , Axsome Therapeutics Inc is Undervalued By 83.56%.

Relative Value

Fair Zone

636.20-654.17

Current Price：104.62

83.56%

Undervalued

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

98.39

P/B

Median3y

44.37

Median5y

42.68

-2.35

FCF Yield

Median3y

-3.84

Median5y

-4.63

Competitors Valuation Multiple

The average P/S ratio for AXSM's competitors is 174.58, providing a benchmark for relative valuation. Axsome Therapeutics Inc Corp (AXSM) exhibits a P/S ratio of 7.64, which is -95.62% above the industry average. Given its robust revenue growth of 61.95%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AXSM.O

Axsome Therapeutics Inc

7.64

Average P/S: 174.58

61.95%